CNTB

SEC source: 0002115875-26-000007 · wk-form4_1790889535.xml · nonDerivative · entry 1

Xanthopoulos Kleanthis Gabriel · CIK 0002115875 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,554

F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.

SEC source: 0001835268-26-000039 · wk-form4_1790889429.xml · nonDerivative · entry 1

LIU JEAN I · CIK 0001241357 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,763

F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding September 30, 2026, rounded down to the nearest whole share.

SEC source: 0001835268-26-000021 · wk-form4_1782937573.xml · nonDerivative · entry 1

LIU JEAN I · CIK 0001241357 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,779

F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the second quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026, rounded down to the nearest whole share.

SEC source: 0001835268-26-000022 · wk-form4_1782937615.xml · nonDerivative · entry 1

Xanthopoulos Kleanthis Gabriel · CIK 0002115875 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,554

F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the second quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares for the 30 days preceding June 30, 2026, rounded down to the nearest whole share.

SEC source: 0001193125-26-253607 · ownership.xml · nonDerivative · entry 1

Huang James · CIK 0001573160 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 13,310,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $2.37 to $2.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.

F2 · ownership.nature: Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, James Huang may be deemed to share beneficial ownership of the Ordinary Shares reported herein, but disclaims such beneficial ownership.

SEC source: 0001193125-26-138012 · ownership.xml · nonDerivative · entry 1

Huang James · CIK 0001573160 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 13,160,000

F1 · ownership.nature: Panacea Venture Healthcare Fund II, L.P. is the record holder of the Ordinary Shares reported herein. James Huang is the sole owner of Panacea Innovation Limited, which is the sole owner of Panacea Venture Healthcare Fund II GP Company, Ltd., which is the general partner of Panacea Venture Healthcare Fund II, L.P. As a result, James Huang may be deemed to share beneficial ownership of the Ordinary Shares reported herein, but disclaims such beneficial ownership.

SEC source: 0001241357-26-000004 · wk-form4_1775161497.xml · nonDerivative · entry 1

LIU JEAN I · CIK 0001241357 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,061

F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share.

SEC source: 0002115875-26-000004 · wk-form4_1775161671.xml · nonDerivative · entry 1

Xanthopoulos Kleanthis Gabriel · CIK 0002115875 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,816

F1 · shares: In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Dr. Xanthopoulos elected to receive fully vested shares in lieu of a portion of cash compensation for his 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Dr. Xanthopoulos for his service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share.